MorphoSys AG (ETR:MOR – Get Rating) shares rose 0.8% on Monday . The company traded as high as €18.34 ($19.93) and last traded at €18.15 ($19.73). Approximately 93,647 shares were traded during trading, a decline of 39% from the average daily volume of 153,687 shares. The stock had previously closed at €18.00 ($19.57).
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. Morgan Stanley set a €12.50 ($13.59) price target on shares of MorphoSys in a research note on Friday, January 6th. JPMorgan Chase & Co. set a €11.00 ($11.96) target price on MorphoSys in a research report on Monday, January 9th. The Goldman Sachs Group set a €12.00 ($13.04) price target on MorphoSys in a research report on Tuesday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft set a €13.00 ($14.13) price objective on MorphoSys in a report on Friday, November 25th.
Get MorphoSys alerts:MorphoSys Stock Up 0.8 %
The company has a market capitalization of $620.02 million and a PE ratio of -1.03. The company has a debt-to-equity ratio of 231.51, a quick ratio of 3.49 and a current ratio of 3.76. The company's 50-day moving average is €15.00 and its 200 day moving average is €18.27.
About MorphoSys
(Get Rating)MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
Featured Articles
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.